Hongbo Yang
 
                    Education
Ph.D., biology, and M.S., statistics, University of Illinois at Urbana-Champaign; B.S., biology, Nankai University
Summary of Experience
Dr. Yang is an expert in health economics and outcomes research (HEOR), with extensive experience in developing comprehensive HEOR strategies to support products throughout their entire life cycles. As part of her diverse portfolio of HEOR case work, she has developed robust launch strategies; generated real-world data (RWD); and created clinical, economic, and humanistic evidence to support product value propositions. Notably, Dr. Yang has led case teams in preparing submissions to health technology assessment (HTA) agencies across the world, including those in the UK, France, Germany, Norway, Australia, Canada, and Japan. She has also conducted numerous studies across various therapeutic areas – such as autoimmune diseases, infectious diseases, diabetes, blood disorders, oncology, women’s health, and rare diseases – and worked across diverse treatment paradigms, including one-time interventions involving cell and gene therapies, as well as recurrent treatment regimens. Dr. Yang’s work has been widely published in peer-reviewed journals and featured at health care conferences.
- 
                                                        Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphomaLeukemia & Lymphoma, 2024 
 2024Dickinson M, Martinez-Lopez J, Jousseaume E, Yang H, Chai X, Xiang C, Wang T, Zhang J, Ramos R, Schuster SJ, Fowler N 
- 
                                                        Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancerProstate Cancer and Prostatic Diseases, 2024 
 2024George DJ, Agarwal N, Ramaswamy K, Klaassen Z, Bitting RL, Russell D, Sandin R, Emir B, Yang H, Song W, Lin Y, Hong A, Gao W, Freedland SJ 
- 
                                                        Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case StudyApplied Health Economics and Health Policy, 2024 
 2024Laetsch T, Zhang J, Hongbo Yang H, Xie Y, Zhang D, Garrison L 
- 
                                                        Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerProstate Cancer and Prostatic Diseases, 2024 
 2024George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ 
- 
                                                        Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathyEuropean Journal of Neurology, 2024 
 2024Labeyrie C, Merkel M, Sethi S, Popadic L, Yang H, Sweetser MT, Lin H, Adams D 
- 
                                                        Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancerThe Prostate, 2024 
 2024Swami U, Xie B, Young C, Ramaswamy K, El-Chaar N, Gao W, Yang H, Wang Y, Mucha L 
- 
                                                        Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia GravisAdvances in Therapy, October 2024 
 2024Smith AG, Wolfe GI, Habib AA, Qi CZ, Yang H, Du M, Chen X, Gelinas D, Brauer E, Phillips G, Saccà F 
- 
                                                        Indirect Treatment Comparison (Itc) of the Efficacy of Vutrisiran and Tafamidis for Hereditary Transthyretin-Mediated Amyloidosis with PolyneuropathyExpert Opinion on Pharmacotherapy, 2023 
 2023
- 
                                                        Healthcare Resource Use and Reimbursement Amount by Site of Care in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell (CAR-T) Therapy - a Retrospective Cohort Study Using CMS 100% Medicare Claims DatabaseLeukemia & Lymphoma, 2023 
 2023Yang H, Bollu V, Lim S, Tesfaye M, Dalal AA, Lax A, Sethi S, Zhao J 
- 
                                                        Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell TransplantationPatient preference and adherence, 2023 
 2023Saini L, Griffin JD, Pandya BJ, Shah MV, Zhou M, Yang H, Song Y, Marshall DA 
- 
                                                        Assessment of women's treatment preferences for vasomotor symptoms due to menopauseExpert Review of Pharmacoeconomics & Outcomes Research, 2023 
 2023Shiozawa A, Thurston RC, Cook E, Yang H, King DD, Kristy RM, Mancuso S 
- 
                                                        Association of menopausal vasomotor symptom severity with sleep and work impairments: a US surveyMenopause, 2023 
 2023DePree B, Shiozawa A, King D, Schild A, Zhou M, Yang H, Mancuso S 
- 
                                                        Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United StatesJournal of International Medical Research, 2022 
 2022Kraus SR, Li J, Kristy RM, Lockefeer A, Yang H, Zhou M, Walker DR 
- 
                                                        Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trialLeukemia & Lymphoma, 2022 
 2022Zeidan AM, Qi CZ, Yang H, Garnham A, Shah MV, Pandya BJ 
- 
                                                        Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel DiseaseAdvances in Therapy, 2022 
 2022Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, Yang H, Azimi N, Strand V, Yarur A 
- 
                                                        The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated DiseasesAdvances in Therapy, 2022 
 2022Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, Yang H, Downes N, Azimi N, Strand V 
- 
                                                        Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparisonLeukemia & Lymphoma, 2022 
 2022Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ 
- 
                                                        Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical TrialsDermatologic Therapy, 2022 
 2022Lebwohl MG, Soliman AM, Yang H, Wang J, Hagan K, Padilla B, Pinter A 
- 
                                                        Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell LymphomaBlood Advances, 2022 
 2022Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G 
- 
                                                        Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United StatesLeukemia & Lymphoma, 2022 
 2022Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V 
- 
                                                        Health care resource utilization and cost burden of hemophilia B in the United StatesBlood Advances, 2021 
 2021Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N 
- 
                                                        Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress testJournal of Nuclear Cardiology, 2021 
 2021Yang H, Faust E, Gao E, Sethi S, Kitt TM, Kristy RM, Spalding JR, Xu Y 
- 
                                                        Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomesEuropean Journal of Haematology, 2021 
 2021Griffin JD, Song Y, Yang H, Freimark J, Shah MV 
- 
                                                        Hemophilia Gene Therapy Value Assessment: Methodological Challenges and RecommendationsValue in Health, 2021 
 2021Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M 
- 
                                                        Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review StudyFrontiers in Medicine, 2021 
 2021Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Hongbo Yang H, Moritz ML 
- 
                                                        Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in JapanTransplantation and Cellular Therapy, 2021 
 2021Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A 
- 
                                                        Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in JapanTransplantation and Cellular Therapy, 2021 
 2021Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A 
- 
                                                        Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemiaBlood Advances, 2021 
 2021Verneris MR, Ma Q, Zhang J, Keating A, Tiwari R, Li J, Yang H, Agarwal A, Pacaud L 
- 
                                                        Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated DiseasesClinical Therapeutics, 2021 
 2021Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V 
- 
                                                        
- 
                                                        Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemiaJournal of Managed Care & Specialty Pharmacy, 2021 
 2021Pandya BJ, Qi CZ, Garnham A, Yang H, Shah MV, Zeidan AM 
- 
                                                        Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasisJournal of Dermatological Treatment, 2021 
 2021Lebwohl M, Soliman AM, Yang H, Wang J, Freimark J, Puig L 
- 
                                                        The Development of Health Technology Assessment in Asia: Current Status and Future TrendsValue in Health Regional Issues, Volume 21, May 2020 
 2020
- 
                                                        A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?Advances in Therapy, 2020 
 2020Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E 
- 
                                                        Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's PerspectiveJournal of Managed Care & Specialty Pharmacy, 2020 
 2020
- 
                                                        Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspectiveJournal of Medical Economics, 2020 
 2020
- 
                                                        An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in JapanJournal of Dermatological Treatment, 2020 
 2020Saeki H, Ishii K, Joshi A, Bensimon AG, Yang H, Kawaguchi I 
- 
                                                        A Longitudinal Assessment of the Impact of Endometriosis on Patients' Salary Growth and Risk of Leaving the WorkforceAdvances in Therapy, 2020 
 2020Estes SJ, Soliman AM, Yang H, Wang J, Freimark J 
- 
                                                        Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims AnalysisDrug Safety, 2020 
 2020Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B 
- 
                                                        Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World PopulationJBMR Plus, 2020 
 2020Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, Yang H, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB 
- 
                                                        A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a US health planJournal of Medical Economics, 2020 
 2020Pandya BJ, Yang H, Schmeichel C, Qi CZ, Shah MV 
- 
                                                        Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims AnalysisJournal of Managed Care & Specialty Pharmacy, 2019 
 2019Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B 
- 
                                                        Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin AmericaAdvances in Therapy, 2019 
 2019Muniz DQ, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Medina ML, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S 
- 
                                                        Factors that impact a patient's experience when undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in the US: A survey of patients, imaging center staff, and physiciansJournal of Nuclear Cardiology, 2019 
 2019Li J, Walker DR, Biesbrock G, Kristy RM, Yang H, Gao E, Koenigsberg S, Spalding JR, Kitt TM 
- 
                                                        Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancerCurrent Oncology, 2019 
 2019Levy BP, J E Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M 
- 
                                                        Insights into the natural history of metachromatic leukodystrophy from interviews with caregiversOrphanet Journal of Rare Diseases, 2019 
 2019Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H 
- 
                                                        Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class AnalysisDiabetes Therapy. Mar 29 2018. 
 2018
- 
                                                        Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and IncomeBritish Journal of Dermatology, 2018 
 2018Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J 
- 
                                                        Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims AnalysisAdvances in Therapy. 2018 Oct;35(10):1639-1655 
 2018Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V 
- 
                                                        Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States2018 Oct;35(10):1564-1577 
 2018Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL 
- 
                                                        Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart StudyEuropean Journal of Haematology. December 22, 2018 
 2018
- 
                                                        A Risk Score for Fluconazole Failure among Patients with CandidemiaAntimicrobial Agents Chemotherapy. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May. 
 2017Yang H, Ostrosky-Zeichner L, Harrington R, Azie N, Li N, Zhao J, Koo V, Wu EQ 
- 
                                                        Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive AspergillosisAdvances in Therapy; 2017 Jan;34(1):207-220. doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 2. 
 2017Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. 
- 
                                                        Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosisJournal of Medical Economics, 2017 October 
 2017
- 
                                                        Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging testsJournal of Medical Economics. Aug 2017;20(8):777-785 
 2017Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ 
- 
                                                        Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prJournal of Medical Economics. Feb 2017;20(2):121-128 
 2017Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S 
- 
                                                        Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or LaparoscopyJournal of Women's Health. Jun 2017;26(6):644-654 
 2017
- 
                                                        Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical ReasonsClinical Therapeutics. Apr 2017;39(4):849-862 e846 
 2017Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M 
- 
                                                        Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumorsAmerican Health and Drug Benefits. November 2017;10(8):408-415 
 2017Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB 
- 
                                                        Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive A(1)Advances in Therapy. Jan 2017;34(1):207-220 
 2017Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J 
- 
                                                        Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims AnalysisAdvances in Therapy. Nov 2017;34(11):2436-2451 
 2017Surrey ES, Soliman AM, Yang H, Du EX, Su B 
- 
                                                        Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment (1)Journal of Medical Economics. Oct 2017;20(10):1056-1065 
 2017
- 
                                                        Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational StudyDiabetes Therapy. Jun 2017;8(3):555-571 
 2017Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R 
- 
                                                        Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized PatientsAntimicrobial Agents and Chemotherapy, 2016 06; 60(6): 3398-3406. e-pub ahead of print 2016/03/24 
 2016Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J. 
- 
                                                        Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prJournal of Medical Economics, 2016 09: 1-8 
 2016Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. 
- 
                                                        Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective studyBMC Infectious Diseases, December 1, 2016 
 2016Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR 
- 
                                                        Brentuximab Vedotin Compared with Other Therapies in Relapsed/Refractory Hodgkin Lymphoma Post ASCT: Median Overall Survival Meta-AnalysisCurr Med Res Opin. 2015 May 7:1-48 
 2015Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D 
- 
                                                        Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical dataCurr Med Res Opin. 2015 May; 31(5):993-1001 
 2015Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D. 
- 
                                                        The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013Am J Obstet Gynecol. 2015 Mar 11 
 2015Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C 
- 
                                                        The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomasCurr Med Res Opin. 2015 Mar; 31(3):537-45 
 2015Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. 
- 
                                                        Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databasesFertil Steril. 2015 Jan; 103(1):163-71 
 2015
- 
                                                        Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western EuropeJ Med Econ. 2014 Dec; 17(12):837-45 
 2014Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H. 
- 
                                                        Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United StatesAppl Health Econ Health Policy. 2014 Feb; 12(1):85-93 
 2014
- 
                                                        Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebecCan J Psychiatry. 2014 Nov; 59(11):597-608 
 2014Lachaine J, De G, Sikirica V, Van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L. 
- 
                                                        Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record reviewCurr Med Res Opin. 2014 Apr; 30(4):537-45 
 2014Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ. 
- 
                                                        
- 
                                                        Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneityJ Med Econ. 2012; 15(6):1078-87 
 2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ 
- 
                                                        Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patientsJ Med Econ. 2012; 15(4):786-95 
 2012Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. 
- 
                                                        Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancerJournal of Medical Economics, 1-26, November 16, 2012 
 2012
- 
                                                        Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-Br J Dermatol. 2012 Dec; 167(6):1374-81 
 2012Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM 
- 
                                                        Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugsPostgrad Med. 2012 Jan; 124(1):124-32 
 2012
- 
                                                        Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancerJ Med Econ. 2011; 14(5):542-52 
 2011
- 
                                                        Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysisJ Med Econ. 2011; 14(3):315-23 
 2011
- 
                                                        Domains of heterochromatin protein 1 required for Drosophila melanogaster heterochromatin spreadingGenetics. 2009 Aug;182(4):967-77. doi: 10.1534/genetics.109.105338. Epub 2009 Jun 1 
 2009Hines KA, Cryderman DE, Flannery KM, Yang H, Vitalini MW, Hazelrigg T, Mizzen CA, Wallrath LL 
- 
                                                        The multiple facets of histone H4-lysine 20 methylationBiochemistry and Cell Biology; 2009 Feb;87(1):151-61. doi: 10.1139/O08-131 
 2009Yang H, Mizzen CA 
- 
                                                        Certain and progressive methylation of histone H4 at lysine 20 during the cell cycleMolecular and Cellular Biology, 2008 Jan;28(1):468-86. Epub 2007 Oct 29 
 2008Pesavento JJ, Yang H, Kelleher NL, Mizzen CA 
- 
                                                        Preferential dimethylation of histone H4 lysine 20 by Suv4-20The Journal of Biological Chemistry; 2008 May 2;283(18):12085-92. doi: 10.1074/jbc.M707974200. Epub 2008 Feb 21 
 2008Yang H, Pesavento JJ, Starnes TW, Cryderman DE, Wallrath LL, Kelleher NL, Mizzen CA 
- 
                                                        Proliferation and apoptosis of smooth muscle cells in benign prostate hyperplasiaChinese Journal of Pathophysiology; 2005, 21: 817-819 
 2005Shi J, Li J, Yang H, Wang K, Wu Q, Zhang J. 
- 
                                                        Association lifetimes of hydrophobic amino acid pairs measured directly from molecular dynamics simulationsJournal of the American Chemical Society, 2003 Nov 19;125(46):13968-9 
 2003Yang H, Elcock AH 
- 
                                                    October 29, 2024
- 
                                                    April 16, 2024
- 
                                                    April 11, 2024
- 
                                                    November 16, 2023
- 
                                                    October 23, 2023
- 
                                                    December 10, 2021
- 
                                                    October 15, 2021
- 
                                                    June 4, 2021
 
         
                                 
                                